Pantothenic Acid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Pantothenic Acid
- Pantothenic Acid (Vitamin B5): From Nutritional Supplementation to Congenital Prothrombin Deficiency
Pantothenic Acid (Vitamin B5): From Nutritional Supplementation to Congenital Prothrombin Deficiency
One-Sentence Summary
Pantothenic acid (Vitamin B5) is a naturally occurring nutrient and dietary-supplement ingredient with no SAHPRA-registered therapeutic indication in South Africa. The TxGNN model’s top prediction links it to Congenital Prothrombin Deficiency, with a prediction score of 99.96%, but this is currently supported by only 1 unrelated clinical trial and no literature — the evidence base does not yet substantiate the prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established — Pantothenic acid is a nutrient (Vitamin B5); no SAHPRA-registered therapeutic indication on file |
| Predicted New Indication | Congenital Prothrombin Deficiency |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for pantothenic acid is not currently available in this evidence pack (flagged as a High-severity data gap). Pantothenic acid is generally known as a precursor of coenzyme A (CoA), which is essential to fatty-acid and energy metabolism, but no established biochemical pathway currently links pantothenic acid to prothrombin (Factor II) synthesis or coagulation cascade regulation.
The single clinical trial identified for this candidate (NCT02392767) investigated a multi-ingredient dietary supplement (L-arginine, Pycnogenol, vitamin K2, alpha-lipoic acid, B-vitamins) on endothelial function in patients with mild-to-moderate hypertension — a study population and endpoint unrelated to congenital prothrombin deficiency. No supporting literature was returned for this drug-disease pair.
Taken together, the reviewer assessment in this evidence pack itself concludes that this is most likely a knowledge-graph artefact — a high TxGNN confidence score without a corroborating mechanistic or clinical signal — rather than a genuine repurposing lead. This is consistent with the assigned evidence level of L5 (model prediction only).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02392767 | NA | Completed | 25 | Randomised, double-blind, cross-over study of a multi-ingredient dietary supplement (containing pantothenic-acid-related B-vitamins) on endothelial function in patients with mild-to-moderate hypertension. Not related to prothrombin deficiency or coagulation (relevance grade: C — unrelated). |
Literature Evidence
Currently no related literature available.
South Africa Market Information
Pantothenic acid has no SAHPRA registrations (0 licenses) and is currently not marketed in South Africa as a registered medicine.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(Note: SAHPRA/PI warning and contraindication data for this product could not be retrieved — flagged as a Blocking data gap that prevents formal safety screening (S1) for this candidate.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The predicted indication (congenital prothrombin deficiency) has no plausible mechanistic link to pantothenic acid and is supported only by one clinically unrelated trial and zero literature — evidence level L5. Combined with the absence of SAHPRA registration and missing PI/safety data, this candidate does not meet the threshold to proceed.
To proceed, the following is needed:
- Mechanism-of-action data confirming (or refuting) any biological pathway between pantothenic acid and prothrombin/coagulation factor synthesis
- SAHPRA-approved Professional Information (warnings, contraindications, interactions) — currently a Blocking data gap
- Targeted literature/trial search specifically on pantothenic acid and coagulation factor disorders, since none currently exists
Note for reviewers: This same evidence pack contains a considerably stronger candidate further down the ranked list — folic acid deficiency anemia (rank 4, evidence level L3, decision stage S1, recommendation Research Question) — supported by a historical mechanistic literature link (pantothenic acid/folic acid co-deficiency anemia) and several supportive B-vitamin-complex trials. It may be a more productive candidate to prioritize than the top-ranked TxGNN score.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.